Michael Callahan, M.D.
Vaccine & Immunotherapy Center, Massachusetts General Hospital
Infectious Disease, Massachusetts General Hospital
|MD University of Alabama School of Medicine 1995|
Dr. Callahan is a physician scientist board certified in internal medicine, infectious disease, tropical medicine (DTM&H) and mass casualty care and is clinical and research faculty at Massachusetts General Hospital/Harvard Medical School, with clinical appointments at King Chulalongkorn Medical Center in Bangkok and visiting clinical faculty in Indonesia, Panama and Nigeria.
From 2005-2012, Dr. Callahan led DARPA's biodefense program, developing novel vaccines and infectious disease therapies, launching 11 companies and bringing 4 novel drugs and vaccines to market, and established Prophecy, an international surveillance and clinical trials network that was first to identify the 2009 pandemic H1N1 virus, the presence of H5N1 in Thailand and the first rapid deployment clinical research capability for catastrophic infectious diseases outbreaks such as Ebola.
Dr. Callahan has served as special advisor on infectious disease to two presidents, the secretaries of Defense and of Health and Human Services, the Office of the Commissioner of the FDA, and served on multiple Institute of Medicine committees of the National Academy of Science.
In 2012 Dr. Callahan was recruited as President of Unither Virology, a United Therapeutics company (UTHR), where he led the National Institute of Health’s 45 million U.S. dollar effort to develop the first drug for dengue. Dr. Callahan has deployed to 7 mass casualty disease outbreaks including Ebola, Marburg, H5N1 and H7N9 bird flu, and MERS.